Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | LPL | P06858 | 2/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953821 | 0.80 | CA2 (0.30) | CA2LPLLIPG | |
| SCHEMBL101282 | 0.78 | CA2 (0.31) | CA2LPLLIPG | |
| SCHEMBL5951421 | 0.70 | — | — | |
| SCHEMBL20021695 | 0.67 | MEN1 (0.30) | — | |
| SCHEMBL29950823 | 0.65 | LPL (0.40) | CA2LPLLIPGENPP2CA4 | |
| SCHEMBL29950928 | 0.65 | CA2 (0.34) | CA2LPLLIPGENPP2CA4 | |
| SCHEMBL19650143 | 0.64 | — | — | |
| SCHEMBL29958168 | 0.64 | CA2 (0.33) | CA2LPLLIPGENPP2CA4 | |
| SCHEMBL29957036 | 0.63 | ENPP2 (0.44) | CA2LPLLIPGENPP2CA4 | |
| SCHEMBL19650142 | 0.61 | CA2 (0.31) | CA2LPLLIPGENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-1663973-B3 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2019-09-25 | — | — | EP | disclosed |
| EP-1663973-B1 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2013-12-25 | — | — | EP | disclosed |
| US-8501784-B2 | 2-pyridone derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2013-08-06 | — | — | US | disclosed |
| US-20120035157-A1 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| US-8063073-B2 | 2-pyridone derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2011-11-22 | — | — | US | disclosed |
| US-20070203129-A1 | 2-Pyridone Derivatives As Neutrophil Elastase Inhibitors And Their Use | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | US | disclosed |
| EP-1663973-A1 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026123-A1 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035157-A1 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | SERPINB1, ELANE, SERPINE1 | CA2 2930/4885LPL 117/4885LIPG 175/4885 |
| US-20070203129-A1 | 2-Pyridone Derivatives As Neutrophil Elastase Inhibitors And Their Use | SERPINB1, ELANE, SERPINE1 | CA2 3009/4885LPL 118/4885LIPG 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.